Sustained Efficacy of Bimekizumab in PsA BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, BKZ, in patients with active PsA and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52. https://t.co/JQ53JV0dvv https://t.co/RQoIXsVnOr